A chronic hypercoagulable state in patients with β‐thalassaemia major is already present in childhood
Open Access
- 24 December 1999
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 107 (4) , 739-746
- https://doi.org/10.1046/j.1365-2141.1999.01758.x
Abstract
A higher than normal incidence of thromboembolic events has been observed in adult patients with β‐thalassaemia major (TM) and certain haemostatic anomalies found in these patients suggest the existence of a chronic hypercoagulable state. Thalassaemic red blood cells (RBC) were demonstrated to facilitate thrombin formation due to altered asymmetry of the membrane phospholipids with enhanced exposure of phosphatidylserine. Since RBC anomalies exist in thalassaemia from the first months of life, we studied markers of hypercoagulability and thrombophilia in 36 adult patients (range 19–38 years) and 26 children (range 2–18 years) with β‐TM. All the patients were in steady state and none had experienced clinical signs or symptoms of thrombosis. Highly elevated urinary levels of 11‐dehydro‐thromboxane B2 and significantly elevated plasma levels of thrombin–antithrombin III (TAT) complexes were observed to the same extent in TM children and adults. The levels of factor II were decreased while factors V, VII + X and plasminogen were within the normal range. The natural coagulation inhibitors, protein C (PC) and protein S (PS) were significantly decreased in all TM patients investigated, regardless of age, but the PS binding protein (C4bBP) and antithrombin III levels were normal. The frequency of other thrombophilic mutations was not increased. Thus, a chronic hypercoagulable state already exists in thalassaemia in childhood and may contribute to the cardiac and pulmonary anomalies and the thrombotic events which occur later.Keywords
This publication has 33 references indexed in Scilit:
- In‐vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with β‐thalassaemia majorBritish Journal of Haematology, 1997
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Erythrocyte membrane vesicles and irreversibly sickled cells bind protein SAmerican Journal of Hematology, 1994
- PADGEM/GMP‐140 expression on platelet membranes from homozygous beta thalassaemic patientsBritish Journal of Haematology, 1993
- Thromboxane Biosynthesis and Platelet Function in Type II Diabetes MellitusNew England Journal of Medicine, 1990
- Cerebral thrombosis in beta-thalassemia/hemoglobin E disease.Stroke, 1990
- Clinical Implications of Prostaglandin and Thromboxane A2FormationNew England Journal of Medicine, 1988
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986
- Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet ActivationNew England Journal of Medicine, 1984
- Abnormal Platelet Functions in β ThalassaemiaScandinavian Journal of Haematology, 1978